vs
Corpay（CPAY）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Corpay的季度营收约是Revvity的1.6倍（$1.2B vs $772.1M），Corpay净利率更高（21.2% vs 12.7%，领先8.4%），Corpay同比增速更快（20.7% vs 5.9%），Corpay自由现金流更多（$760.3M vs $161.8M），过去两年Corpay的营收复合增速更高（15.5% vs 9.0%）
Corpay总部位于美国佐治亚州亚特兰大，是专业的支付与支出管理服务提供商，旗下系统及服务可帮助客户高效管控采购、支付全流程的相关费用，核心业务覆盖车辆相关支出、住宿支出及企业支付三大领域。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CPAY vs RVTY — 直观对比
营收规模更大
CPAY
是对方的1.6倍
$772.1M
营收增速更快
CPAY
高出14.8%
5.9%
净利率更高
CPAY
高出8.4%
12.7%
自由现金流更多
CPAY
多$598.5M
$161.8M
两年增速更快
CPAY
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $264.5M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 45.2% | 14.5% |
| 净利率 | 21.2% | 12.7% |
| 营收同比 | 20.7% | 5.9% |
| 净利润同比 | 7.5% | 3.9% |
| 每股收益（稀释后） | $3.74 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPAYRVTY
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $1.0B | $664.8M | ||
| Q4 24 | $1.0B | $729.4M | ||
| Q3 24 | $1.0B | $684.0M | ||
| Q2 24 | $975.7M | $691.7M | ||
| Q1 24 | $935.3M | $649.9M |
净利润CPAYRVTY
| Q4 25 | $264.5M | $98.4M | ||
| Q3 25 | $277.9M | $46.7M | ||
| Q2 25 | $284.2M | $53.9M | ||
| Q1 25 | $243.2M | $42.2M | ||
| Q4 24 | $246.0M | $94.6M | ||
| Q3 24 | $276.4M | $94.4M | ||
| Q2 24 | $251.6M | $55.4M | ||
| Q1 24 | $229.8M | $26.0M |
毛利率CPAYRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率CPAYRVTY
| Q4 25 | 45.2% | 14.5% | ||
| Q3 25 | 44.6% | 11.7% | ||
| Q2 25 | 43.5% | 12.6% | ||
| Q1 25 | 42.5% | 10.9% | ||
| Q4 24 | 47.2% | 16.3% | ||
| Q3 24 | 45.5% | 14.3% | ||
| Q2 24 | 44.4% | 12.4% | ||
| Q1 24 | 42.5% | 6.8% |
净利率CPAYRVTY
| Q4 25 | 21.2% | 12.7% | ||
| Q3 25 | 23.7% | 6.7% | ||
| Q2 25 | 25.8% | 7.5% | ||
| Q1 25 | 24.2% | 6.4% | ||
| Q4 24 | 23.8% | 13.0% | ||
| Q3 24 | 26.9% | 13.8% | ||
| Q2 24 | 25.8% | 8.0% | ||
| Q1 24 | 24.6% | 4.0% |
每股收益（稀释后）CPAYRVTY
| Q4 25 | $3.74 | $0.86 | ||
| Q3 25 | $3.91 | $0.40 | ||
| Q2 25 | $3.98 | $0.46 | ||
| Q1 25 | $3.40 | $0.35 | ||
| Q4 24 | $3.43 | $0.77 | ||
| Q3 24 | $3.90 | $0.77 | ||
| Q2 24 | $3.52 | $0.45 | ||
| Q1 24 | $3.12 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $919.9M |
| 总债务越低越好 | $10.0B | — |
| 股东权益账面价值 | $3.9B | $7.3B |
| 总资产 | $26.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 2.58× | — |
8季度趋势，按日历期对齐
现金及短期投资CPAYRVTY
| Q4 25 | $2.4B | $919.9M | ||
| Q3 25 | $2.0B | $931.4M | ||
| Q2 25 | $2.2B | $991.8M | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.3B | $1.2B | ||
| Q2 24 | $1.4B | $2.0B | ||
| Q1 24 | $1.3B | $1.7B |
总债务CPAYRVTY
| Q4 25 | $10.0B | — | ||
| Q3 25 | $8.1B | — | ||
| Q2 25 | $8.1B | — | ||
| Q1 25 | $8.2B | — | ||
| Q4 24 | $8.0B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CPAYRVTY
| Q4 25 | $3.9B | $7.3B | ||
| Q3 25 | $4.1B | $7.4B | ||
| Q2 25 | $3.9B | $7.6B | ||
| Q1 25 | $3.5B | $7.6B | ||
| Q4 24 | $3.1B | $7.7B | ||
| Q3 24 | $3.1B | $7.9B | ||
| Q2 24 | $2.8B | $7.9B | ||
| Q1 24 | $3.3B | $7.8B |
总资产CPAYRVTY
| Q4 25 | $26.4B | $12.2B | ||
| Q3 25 | $19.7B | $12.1B | ||
| Q2 25 | $20.4B | $12.4B | ||
| Q1 25 | $18.5B | $12.4B | ||
| Q4 24 | $18.0B | $12.4B | ||
| Q3 24 | $17.6B | $12.8B | ||
| Q2 24 | $16.2B | $13.4B | ||
| Q1 24 | $15.8B | $13.4B |
负债/权益比CPAYRVTY
| Q4 25 | 2.58× | — | ||
| Q3 25 | 1.99× | — | ||
| Q2 25 | 2.07× | — | ||
| Q1 25 | 2.37× | — | ||
| Q4 24 | 2.56× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $812.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $760.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 60.9% | 21.0% |
| 资本支出强度资本支出/营收 | 4.2% | 2.6% |
| 现金转化率经营现金流/净利润 | 3.07× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $1.3B | $509.4M |
8季度趋势，按日历期对齐
经营现金流CPAYRVTY
| Q4 25 | $812.7M | $182.0M | ||
| Q3 25 | $-378.9M | $138.5M | ||
| Q2 25 | $1.1B | $134.3M | ||
| Q1 25 | $-74.2M | $128.2M | ||
| Q4 24 | $648.7M | $174.2M | ||
| Q3 24 | $400.8M | $147.9M | ||
| Q2 24 | $540.9M | $158.6M | ||
| Q1 24 | $350.2M | $147.6M |
自由现金流CPAYRVTY
| Q4 25 | $760.3M | $161.8M | ||
| Q3 25 | $-429.8M | $120.0M | ||
| Q2 25 | $1.1B | $115.5M | ||
| Q1 25 | $-118.9M | $112.2M | ||
| Q4 24 | $604.6M | $149.8M | ||
| Q3 24 | $355.0M | $125.6M | ||
| Q2 24 | $496.8M | $136.6M | ||
| Q1 24 | $309.0M | $129.7M |
自由现金流率CPAYRVTY
| Q4 25 | 60.9% | 21.0% | ||
| Q3 25 | -36.7% | 17.2% | ||
| Q2 25 | 98.7% | 16.0% | ||
| Q1 25 | -11.8% | 16.9% | ||
| Q4 24 | 58.4% | 20.5% | ||
| Q3 24 | 34.5% | 18.4% | ||
| Q2 24 | 50.9% | 19.7% | ||
| Q1 24 | 33.0% | 20.0% |
资本支出强度CPAYRVTY
| Q4 25 | 4.2% | 2.6% | ||
| Q3 25 | 4.3% | 2.6% | ||
| Q2 25 | 4.8% | 2.6% | ||
| Q1 25 | 4.5% | 2.4% | ||
| Q4 24 | 4.3% | 3.4% | ||
| Q3 24 | 4.4% | 3.3% | ||
| Q2 24 | 4.5% | 3.2% | ||
| Q1 24 | 4.4% | 2.7% |
现金转化率CPAYRVTY
| Q4 25 | 3.07× | 1.85× | ||
| Q3 25 | -1.36× | 2.97× | ||
| Q2 25 | 4.01× | 2.49× | ||
| Q1 25 | -0.30× | 3.03× | ||
| Q4 24 | 2.64× | 1.84× | ||
| Q3 24 | 1.45× | 1.57× | ||
| Q2 24 | 2.15× | 2.87× | ||
| Q1 24 | 1.52× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPAY
| Vehicle Payments | $572.9M | 46% |
| Corporate Payments | $480.8M | 39% |
| Lodging Payments | $112.5M | 9% |
| Other Operating Segments | $82.1M | 7% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
